Table S2. Previously reported cases of PD-1 inhibitor exposure in liver transplant patients.
| ID | Age | Transplant to immunotherapy (years) | Organ transplant | Malignancy | Immunotherapy | Number of immunotherapy doses | Time to graft rejection (days) | Immune suppression | Organ rejection | Response to immunotherapy | PFS (months) | Ref |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 62 | 6 | Liver | Malignant peripheral nerve sheath tumor | Ipilimumab & pembrolizumab | 4/25 | – | Sirolimus, mycophenolate mofetil | No | PR | 17* | (29) |
| 2 | 20 | 4 | Liver | FL-HCC | Nivolumab | 2 | 19 | Sirolimus | Yes | – | – | (14) |
| 3 | 14 | 3 | Liver | FL-HCC | Nivolumab | 1 | 7 | Tacrolimus | Yes | – | – | (14) |
| 4 | 70 | 8 | Liver | HCC | Pembrolizumab | – | N/A | Tacrolimus | No | PD | 3 | (15) |
| 5 | 54 | 13 | Liver | Non-small cell lung cancer | Nivolumab | 3 | N/A | Tacrolimus, everolimus, prednisone | No | PD | 1.5 | (16) |
| 6 | 41 | – | Liver | HCC | Nivolumab | 15 | N/A | Tacrolimus | No | PD | 3.5 | (20) |
| 7 | 35 | 20 | Liver | Melanoma | Pembrolizumab | 2 | N/A | Tacrolimus | No | CR | 6* | (22) |
| 8 | 57 | 3 | Liver | HCC | Pembrolizumab & sorafenib | 14 | N/A | mTOR inhibitor, tacrolimus | No | CR | 10* | (21) |
| Median | 68 | 6 | N/A | N/A | N/A | N/A | 13 | N/A | N/A | N/A | 6 | N/A |
*, denotes ongoing response; –, denotes that data not available for evaluation. ID, patient identification; SCC, squamous cell carcinoma; FL-HCC, fibrolamellar hepatocellular carcinoma; PD, progressive disease; PR, partial response; Ref, references; N/A, not applicable.